NCT06111859

Brief Summary

Liver stiffness is a marker for scarring of the liver, which occurs after damage from various liver conditions. Scarring prevents normal liver function and can lead to liver failure. Fatty liver is a common cause of liver damage and can contribute to scarring. Currently, liver biopsy serves as the 'gold standard' for assessing the degree of liver scarring and fatty infiltration, guiding treatment decisions. However, liver biopsy poses a significant risk of death and unpleasant side effects, including internal bleeding and pain. Moreover, due to the small sample of liver tissue obtained during the biopsy, the results can be misleading and may not provide an accurate overview of the liver's health. Therefore, there is an unmet need for a non-invasive method of measuring liver stiffness and fat content. Ultrasound-based methods utilize various properties of ultrasound waves to assess liver stiffness and fat levels. This study aims to recruit 100-120 patients with chronic liver disease. The investigators will assess liver stiffness and fat levels during patients' hospital visits for routine scans, biopsies, or clinic appointments. The resulting measurements of liver stiffness and fat obtained through ultrasound-based methods will be compared to patients' routine liver biopsies, routine FibroScan results (another non-invasive method routinely used in clinical care to assess patients' liver stiffness), and other non-invasive severity scores (calculated from results obtained from patients' routine blood tests, providing an overview of the extent of liver damage).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
180

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 2, 2023

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

September 14, 2023

Completed
2 months until next milestone

First Posted

Study publicly available on registry

November 1, 2023

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 2, 2025

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 2, 2025

Completed
Last Updated

November 1, 2023

Status Verified

October 1, 2023

Enrollment Period

2 years

First QC Date

September 14, 2023

Last Update Submit

October 26, 2023

Conditions

Keywords

ElastographyFat Quantification LiverChronic liver diseaseNAFLDMAFLDHepatitisCirrhosis

Outcome Measures

Primary Outcomes (2)

  • Diagnostic accuracy of liver elastography compared to histological staging

    Comparison of ultrasound elastography measures and biopsy based fibrosis scores

    3 years

  • Diagnostic accuracy of liver fat quantification compared to histological assessment

    Comparison of ultrasound fat quantification measures and biopsy based fat percentages

    3 years

Study Arms (1)

Liver Biopsy Cohort

EXPERIMENTAL
Diagnostic Test: Ultrasound based Elastography and fat quantification

Interventions

Correlation of ultrasound-based elastography and fat quantification on liver biopsy

Liver Biopsy Cohort

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \>=18 years old
  • Male or Female
  • Suspected chronic liver disease based on clinical history, serum biochemistry, prior imaging or prior liver biopsy
  • Willing and able to provide written informed consent.

You may not qualify if:

  • Liver transplantation within the last six months
  • Suspected or known acute liver disease
  • Focal liver lesion(s)
  • Age \<18 years old
  • Pregnant women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nuran Seneviratne

London, SE13 5FX, United Kingdom

RECRUITING

MeSH Terms

Conditions

Liver CirrhosisFatty LiverNon-alcoholic Fatty Liver DiseaseHepatitisFibrosis

Condition Hierarchy (Ancestors)

Liver DiseasesDigestive System DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Paul Sidhu

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 14, 2023

First Posted

November 1, 2023

Study Start

January 2, 2023

Primary Completion

January 2, 2025

Study Completion

July 2, 2025

Last Updated

November 1, 2023

Record last verified: 2023-10

Data Sharing

IPD Sharing
Will not share

Locations